The Journal of Immunology, Vol 140, Issue 12 4231-4237, Copyright © 1988 by American Association of Immunologists

ARTICLES

Generation and characterization of monoclonal antibodies specific for the human IFN-gamma receptor

KC Sheehan, J Calderon and RD Schreiber
Department of Pathology, Washington University School of Medicine, St. Louis, MO 63110.

Purified preparations of the human IFN-gamma R derived from placental membranes were used to produce receptor-specific murine mAb. Supernatants from growth-positive wells were screened for their ability to block binding of 125I-IFN-gamma to human placental membranes. Ten inhibitory cultures were identified. Two of these (GIR-208 and GIR-301) abrogated all binding of radioligand to either intact placental membranes or soluble, purified IFN-gamma R. Three others (GIR-72, 76 and 94) showed moderate blocking activity (65, 59, and 49%, respectively) whereas the remaining five (GIR-57, 67, 83, 109, and 153) blocked binding to a low but significant extent (20 to 40%). Specificity experiments demonstrated that the antibodies reacted with the receptor and not the ligand (IFN-gamma). None of the antibodies reacted with IFN-gamma by ELISA. Moreover, GIR-208 and GIR-301, but not isotype-matched controls, identified the receptor by Western blot analysis. GIR-208 and GIR-301 also completely abrogated binding of 125I- IFN-gamma to either mononuclear phagocytes (U937) or human fibroblasts (WISH). Competition experiments revealed that GIR-208 and GIR-301 recognized similar epitopes on the IFN-gamma R and that these (or this) epitopes were identical to or linked to the ligand binding site of the receptor. In addition, both antibodies inhibited development of IFN- gamma-dependent anti-viral activity in WISH cells in a dose-dependent fashion. These data thus indicate that the IFN-gamma R expressed on human placental cells, mononuclear phagocytes, and fibroblasts are similar.

This article has been cited by other articles:

				M. Scortegagna, C. Cataisson, R. J. Martin, D. J. Hicklin, R. D. Schreiber, S. H. Yuspa, and J. M. Arbeit HIF-1{alpha} regulates epithelial inflammation by cell autonomous NF{kappa}B activation and paracrine stromal remodeling Blood, April 1, 2008; 111(7): 3343 - 3354. [Abstract] [Full Text] [PDF]

				J. B. Swann, Y. Hayakawa, N. Zerafa, K. C. F. Sheehan, B. Scott, R. D. Schreiber, P. Hertzog, and M. J. Smyth Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function J. Immunol., June 15, 2007; 178(12): 7540 - 7549. [Abstract] [Full Text] [PDF]

				J. K. Riley, K. Takeda, S. Akira, and R. D. Schreiber Interleukin-10 Receptor Signaling through the JAK-STAT Pathway. REQUIREMENT FOR TWO DISTINCT RECEPTOR-DERIVED SIGNALS FOR ANTI-INFLAMMATORY ACTION J. Biol. Chem., June 4, 1999; 274(23): 16513 - 16521. [Abstract] [Full Text] [PDF]

				M. R. MacDonald, M. W. Burney, S. B. Resnick, and H. W. Virgin IV Spliced mRNA Encoding the Murine Cytomegalovirus Chemokine Homolog Predicts a beta  Chemokine of Novel Structure J. Virol., May 1, 1999; 73(5): 3682 - 3691. [Abstract] [Full Text]

				D. H. Kaplan, A. C. Greenlund, J. W. Tanner, A. S. Shaw, and R. D. Schreiber Identification of an Interferon-[IMAGE] Receptor alpha Chain Sequence Required for JAK-1 Binding J. Biol. Chem., January 5, 1996; 271(1): 9 - 12. [Abstract] [Full Text] [PDF]